Our Team

Led by Dr. Bekim Sadikovic, the Scientific and Clinical Director of the Clinical Genome Centre in London, Canada, the team at EpiSign™ Inc. has developed the first-ever clinically validated epigenetic test that can provide more accurate diagnoses for rare diseases, particularly in cases where traditional testing methods fail to provide a conclusive result.

The team collaborates with institutions across Canada to measure the clinical impact of EpiSign™ across the country through the EpiSign™-CA Clinical Trial. EpiSign Inc. is also implementing the technology internationally in collaboration with institutions across 15 countries.

Additionally, the team's ongoing research continues to uncover DNA methylation patterns, or episignatures, for new conditions and disorders that expand the ever-growing EpiSign™ Knowledge Database.